20 results about "Antithrombotic Agent" patented technology

The invention provides application of an SNP (Single Nucleotide Polymorphism) marker of MIA2 in predicting the curative effect of an antithrombotic drug on thrombus, and belongs to the fields of molecular biology and cardiovascular medicine. According to the application disclosed by the invention, one or more of rs11845046 and rs10134365 of the MIA2 gene is found to be related to the prediction of the curative effect of dabigatran on thrombus for the first time. Gene polymorphism analysis and an ROC curve verify that the curative effect of an NVAF patient after the NVAF patient is treated by using the antithrombotic drug is related to the genotypes of rs11845046 and rs10134365 of the MIA2 gene in a patient sample, and when the genotype of the rs11845046 is GG or the genotype of the rs10134365 is CC, the drug effect of the subject taking the antithrombotic drug is good but the probability of bleeding events is increased.

The invention discloses a chondroitin sulfate oligosaccharide derivative and a preparation method and application thereof.The chondroitin sulfate oligosaccharide derivative is shown in the formula (I), the definition of substituent groups in the formula is shown in the specification, and the derivative comprises di-, tetra-and hexasaccharide derivatives of chondroitin sulfate B and T, has endogenous anticoagulation and anti-inflammatory activity, and can be used for preparing the chondroitin sulfate oligosaccharide derivative. The compound can be developed into anticoagulant and antithrombotic drugs.

The invention discloses an application of PEAR1 gene polymorphism in predicting the bleeding risk of a non-valvular atrial fibrillation patient under the treatment of an antithrombotic drug. The specific related SNP site is rs12407843, further research is carried out in healthy people and NVAF patients, and it is found that when the rs12407843 genotype is GG, the antithrombotic efficacy of a subject taking the antithrombotic drug is better than that of GA and AA carriers, but the probability of bleeding events is increased. The invention further discloses a method, a system and equipment for predicting the curative effect of the antithrombotic drug after thrombus treatment, so that a doctor is assisted in evaluating the treatment effect of a thrombus patient, and a clinician is guided to formulate a personalized treatment scheme for the patient.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in the preparation of anticoagulant or antithrombotic drugs. The banana fruit extract provided by this invention contains flavonoids, polyphenols, polysaccharides, hydroxyanthraquinones, triterpenoids, and other components. Flavonoids and polyphenols have been widely proven to have anti-inflammatory and antioxidant effects, which can synergistically enhance the anticoagulant effect. The high potassium content of banana fruit can indirectly improve vascular function by regulating sodium-potassium balance. The banana fruit extract provided by this invention can inhibit platelet production or promote platelet metabolism, prolong clotting time, and inhibit platelet aggregation. Its natural plant components interfere with platelet aggregation by inhibiting the production of thromboxane A2, achieving anticoagulant and antithrombotic effects. The mechanism of action of banana fruit extract differs from traditional anticoagulants such as heparin, reducing the risk of bleeding. Its natural component characteristics provide a direction for the development of novel plant-derived anticoagulant drugs.

The present disclosure provides use of icaritin in preparing a drug for preventing and treating a bleeding disorder and belongs to the field of medicine. The icaritin can relieve platelet dysfunction, shorten thromboplastin time, and promote blood coagulation, and can be used for preventing and treating the bleeding disorder, especially for treating hemorrhagic transformation after cerebral infarction, gastrointestinal bleeding caused by a thrombolytic or antithrombotic drug for cerebral infarction, or a bleeding complication of a thrombolytic or antithrombotic drug for myocardial infarction.

The invention relates to the field of pharmaceutical preparations, in particular to an antithrombotic aspirin composite sustained release tablet and a preparation process thereof. The preparation process of the antithrombotic aspirin composite sustained-release tablet comprises the following steps: preparing the composite carrier, preparing the drug-loaded compound and preparing the aspirin composite sustained-release tablet. The preparation method comprises the following steps: reacting L-methionine with 1, 4-butanediol to prepare an intermediate A, reacting the intermediate A with di-p-nitrophenyl adipate to prepare an intermediate B, reacting the intermediate B with carboxyl-terminated mPEG to obtain an amphipathic composite carrier, and loading aspirin and tanshinone IIA by using the composite carrier to obtain the aspirin-tanshinone IIA loaded aspirin-tanshinone IIA loaded aspirin-tanshinone IIA loaded aspirin-tanshinone IIA loaded aspirin-tanshinone IIA loaded aspirin-tanshinone. The preparation method comprises the following steps: preparing a medicine-carrying compound, mixing the medicine-carrying compound with other raw materials to prepare a sustained-release tablet, oxidizing and releasing the antithrombotic medicines aspirin and tanshinone IIA by the methylthio group of the medicine-carrying compound, and meanwhile, protecting the aspirin from being oxidized and hydrolyzed by reducing the level of active oxygen, so that the controlled-release effect of the medicines is achieved, and local precise release of the medicines is realized.

The application discloses a 5,6-diphenylpyrazine-2-azacycle compound and a preparation method and application thereof. The 5,6-diphenylpyrazine-2-azacycle compound is synthesized by a more simple and economical method, and it is found through anti-platelet aggregation activity detection that the prepared 5,6-diphenylpyrazine-2-azacycle compound has excellent anti-platelet aggregation activity and small toxic side effect, and can be used as an active ingredient of an antithrombotic drug. In addition, the activity of the synthesized 5,6-diphenylpyrazine-2-azacycle compound is greatly influenced by chiral compounds, and the activity of an R-type compound is obviously greater than that of an S-type compound, so that the R-type compound can play a more excellent antithrombotic effect as an active ingredient of an IP receptor agonist or other antithrombotic drug.

Disclosed is applicability in novel uses of a DO3A-based material containing a gadolinium complex as an antithrombotic agent or a coagulant, on the basis of a discovery finding that the DO3A-based material containing the gadolinium complex which has been used as an anti-inflammatory agent has a novel effect of suppressing a thrombus induced by thrombin or dissolving blood, without being involved in the function of platelet action which stops bleeding at a damaged or injured area.

The invention relates to ADAMTS13 protein variants comprising residues 1 to 685 of ADAMTS13 and wherein one or more N-linked glycosylation sites are added as compared to wild-type ADAMTS13 and / or one or more existing N-linked glycosylation sites are shifted as compared to wild-type ADAMTS13. The invention further relates to compositions comprising such ADAMTS13 variants, methods for their preparation and uses thereof, in particular as an antithrombotic agent, and in the treatment of thrombotic disease, thrombotic microangiopathy, thrombotic thrombocytopeniaurpura (TTP), hemolytic-uremic syndrome (HUS), ischemic stroke, systemic thrombosis, COVID19, antiphospholipid syndrome, pre-eclampsia / HELLP syndrome, sepsis and sickle cell disease.

The application discloses a 5,6-diphenylpyrazine-2-piperidine compound and a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The 5,6-diphenylpyrazine-2-piperidine compound has simple structure, short synthesis route and low synthesis cost, and through in-vitro anti-platelet aggregation activity detection, it is found that the prepared 5,6-diphenylpyrazine-2-piperidine compound has excellent anti-platelet aggregation activity, and can play a more excellent thrombus prevention and treatment effect as an active ingredient of an antithrombotic drug.

The invention discloses application of phytosphingosine in preparation of a platelet activator, a platelet activation method and a platelet function detection kit, in particular to a method based on PHS accumulation and platelet activation, and solves the problems of low efficiency and weak pathological correlation of an exogenous activator. In addition, the invention also discloses a main application scene of applying the PHS to platelet activation, which covers preparation of a platelet activator, in-vitro platelet function detection, MPN disease model construction and antithrombotic drug screening.

The application discloses an endothelium-targeting controlled-release anti-thrombotic drug intelligent monitoring biodegradable heart occluder, and relates to the field of medical devices, which comprises an occluder body and a sheath pipe for regulating and controlling the occluder body, wherein the occluder body is composed of a double-disc-shaped biological skeleton, a fixed deformation body and a biological flow-blocking film; the double-disc-shaped biological skeleton is composed of two mutually symmetrical adhering discs forming left and right heart disc surfaces; a stent outer disc is arranged around the side surface of the adhering disc; a double-layer anti-thrombotic drug controlled-release layer is arranged on the surface of the stent outer disc; the two adhering discs are tightly connected with the fixed deformation body; an ultrasonic blood flow sensor is arranged in the fixed deformation body; an impedance sensor is arranged on one side of the ultrasonic blood flow sensor in the fixed deformation body; and the biological flow-blocking film is arranged on the surface of the two adhering discs on the opposite side. The occluder is periodically degraded in the body of a patient to reduce complications caused by foreign matter retention, and is used for thrombus formation on the surface of the occluder, so that local low-dose anti-thrombotic drugs are controlled and released, thereby reducing the systemic adverse reactions caused by long-term oral administration of anti-thrombotic drugs after occlusion. The thrombus risk and the endothelialization process of the occluder are dynamically monitored to assist the repair and regeneration of heart tissue.

An anticoagulant phenyl-linked heparin oligosaccharide dimer, a preparation method therefor and use thereof are provided. The anticoagulant phenyl-linked heparin oligosaccharide dimer has a structure as represented by general formula I, and the phenyl may be replaced with substituted phenyl, heteroaryl or substituted heteroaryl. The described phenyl-linked heparin oligosaccharide dimer may be synthesized in fewer steps, has a significantly higher total yield, potent and specific antithrombin-dependent anti-Factor Xa activity without significant anti-FactorIIa activity, the anticoagulant activity may be efficiently neutralized by protamine sulfate, has excellent pharmacokinetic profiles, making it suitable for the preparation of novel anticoagulant and antithrombotic drugs that are cost-effective, higher-quality and safer.

The application belongs to the technical field of genetic engineering, and particularly relates to a recombinant collagen type III with endothelialization promotion and low platelet adhesion, a preparation method and application thereof. The recombinant collagen type III retains a functional site in human natural collagen type III for promoting endothelial cell combination, and a key site for platelet combination is directionally replaced to reduce platelet adhesion, and the amino acid sequence is designed as a repeatable unit to enhance functional activity. The recombinant collagen can be expressed in a host cell through genetic engineering and purified to obtain. The obtained recombinant collagen type III has the characteristics of promoting endothelialization and reducing the risk of thrombosis, and is suitable for cardiovascular stent coating, artificial blood vessels and other blood contact instruments, and can be used as an active ingredient in the preparation of vascular repair or antithrombotic drugs.

This invention discloses a class of 1,4-epoxynaphthalene-2,3-dicarboxylic acid compounds, their preparation methods, and their applications in the preparation of antithrombotic drugs. The 1,4-epoxynaphthalene-2,3-dicarboxylic acid compounds have structures as shown in formula (I) 1, 2, 3, 4, or 5. Compounds 1, 2, 3, 4, 5, or 6 containing the 1,4-epoxynaphthalene-2,3-dicarboxylic acid skeleton are novel compounds that exhibit significant inhibitory effects on venous thrombosis in zebrafish. They can be used to prepare antithrombotic drugs for the prevention and treatment of cardiovascular and cerebrovascular diseases. Therefore, this invention provides candidate compounds for the development of new antithrombotic drugs and is of great significance for the development of marine drug resources in China.

The application discloses an anti-thrombotic drug derivative carbon dot and a preparation method and application thereof. The method comprises the following steps: selecting an anti-thrombotic drug as a precursor, wherein the anti-thrombotic drug comprises at least one of an anti-platelet drug with a drug efficacy group, an anti-coagulation drug with a drug efficacy group and a fibrinolytic drug with a drug efficacy group, the molecular weight of the anti-thrombotic drug is 100-2000 Da, the thermal stability decomposition temperature is greater than or equal to 200 DEG C, and the drug efficacy group comprises at least one of a sulfonic acid group, an acetoxy group, an indole ring and a coumarin structure; performing gradient carbonization treatment on the precursor in multiple temperature zones, wherein the multiple temperature zones comprise a low-temperature zone capable of retaining the drug efficacy group, a medium-temperature zone capable of regulating the proportion of carbon hybridization and a high-temperature zone capable of performing heteroatom doping; and performing purification and drying treatment to obtain the anti-thrombotic drug derivative carbon dot. The anti-thrombotic drug derivative carbon dot obtained by the preparation method has both thrombolytic function and high safety, and can relieve the problem of imbalance between the curative effect and safety of the existing anti-thrombotic drug.

The invention belongs to the technical field of biological medicine, and particularly relates to earthworm anticoagulant oligopeptide and application thereof. The invention relates to an anticoagulant oligopeptide, which is found by combining the activity-directed separation of pheretima asper (E. Perriver) with the screening of an AI (artificial intelligence) prediction model. The amino acid sequence of the oligopeptide is LMWFSDRNK; the oligopeptide regulates thrombin in an allosteric manner, enhances the combination of thrombin and antithrombin, and can effectively inhibit blood coagulation and thrombus formation at in-vivo and in-vitro levels; the oligopeptide has a remarkable anticoagulant effect and is suitable for research and development of antithrombotic drugs.

The application discloses a kind of methods for constructing deep vein thrombosis mouse model by regulating Pyk2 gene expression.The method comprises the following steps: constructing knockdown or overexpression vector for Pyk2 gene; by tail vein injection, the vector is introduced into mouse in vivo, the in vivo transient regulation of Pyk2 gene is realized; the inferior vena stenosis method is used to induce deep vein thrombosis; the thrombus macroscopic morphology, wet weight, length and histopathology are detected.The application overcomes the limitation of existing gene knockout model, such as congenital, irreversible and systemic deletion, realizes the targeted, temporary and bidirectional flexible regulation of Pyk2 gene in vascular tissue, and the model has high stability and good repeatability.The model can simulate the pathological state under the same expression level of Pyk2, and is suitable for the screening, evaluation and deep vein thrombosis pathogenesis research of antithrombotic drugs.

The application belongs to the technical fields of polypeptide and biological medicine, and particularly relates to a polypeptide SR14 and application thereof. The amino acid sequence of the polypeptide SR14 is SCEPCQTLAVRSYR. The polypeptide SR14 composed of the amino acids can be effectively combined with a platelet receptor, interfere with the aggregation of thrombin-activated platelets, and then achieve the effect of anti-thrombus. Meanwhile, the polypeptide SR14 has a low risk of bleeding, and can be used for the preparation of anti-thrombus drugs.